Rewired.GG Makes Europe’s Largest Ever esports Team Investment
7.11.2019 10:00:00 EET | Business Wire | Press release
Rewired.GG, the €50m esports venture fund that invests in the global growth of esports, is delighted to announce that it has invested a further €14 million into Team Vitality, taking its total investment to date to €34 million. Today also marks the opening of the new multi-million euro Team Vitality headquarters in Paris, called V.Hive, which will be open to the public. In a world’s first for an esports team, the 10,700 sq ft V.Hive has more than 530 sq ft of store front in the bustling heart of Paris, and will offer engaging esports discoveries and experiences to anyone who walks in.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191106005183/en/
Team Vitality Counter Strike players (from left to right): Alex 'ALEX' McMeekin, Cédric 'RpK' Guipouy, Mathieu 'ZywOo' Herbaut, Dan 'apEX' Madesclaire. (Photo: Business Wire)
Team Vitality is one of the biggest esports teams in Europe and boasts some of the world’s top esports players and coaches. It is one of only ten European esports teams in the League of Legends European Championship franchise; and has recently won the 2019 World Championship for Rocket League, won the 7th season of the prestigious ECS tournament for Counter-Strike:Global Offensive and took 3rd place in the 2019 FIFA World Championship. It is also one of only a few esports teams with blue chip sponsors such as Orange, Renault, Red Bull and adidas.
Rewired.GG forecasts that esports will rival traditional sports such as soccer and basketball and will be a major investment category for institutional investors, funds and investment managers. By 2020 it is estimated that the monthly global esports audience size will be nearly 600 million*, equivalent to the current global audience of the English Premier League.
Today’s investment, along with the €20 million that Team Vitality received from Rewired.GG in November 2018, is thought to be the largest investment into a European esports team to date. The Team, which was founded in 2013 with €10,000, aims to be one of the world’s first $1 billion esports teams.
The funds will be used to support the continued growth of Team Vitality as the team pursues further expansion across India and China, where it is acquiring new players and launching a network of esports academies. Funds will also be used to acquire new players and to launch new lines of merchandise globally: as well as opening V.Hive, the team has also today launched its first Team Vitality brand of limited-edition adidas trainers.
As with any major sport, the business of esports is based on media rights, advertising, prize money, merchandise, sponsorship and partnerships. Revenue from these are growing exponentially.
In 2017 it was estimated that esports generated $655 million in annual revenue, including 38% from sponsorships and 14% from media rights. By 2022, it is forecast that media rights will reach 40% of total esports revenue and that total global esports monetization will reach $3bn.*
CEO of Team Vitality, Nicolas Maurer said:
“In 2013 we started Team Vitality with €10,000. Today Team Vitality has built amazing teams that regularly win tournaments all over the world, and a strong brand that is backed by our amazing and dedicated fans and our premium sponsors. Receiving further backing by Rewired.GG after the initial investment of €20M in November 2018 is a testament to the strength not only of the team but also a comment on the growth of the sector as a whole. This investment will go towards continuing to turn Team Vitality into a global esports brand and we look forward to providing further updates on our future wins as we continue to pursue V for Victory.”
Amit Jain, Principal at Rewired.GG commented:
“Any industry with an audience that’s growing rapidly into hundreds of millions is hugely exciting and esports is no exception. We’ve seen the current esports trend many times before in the tech sector: first the number of eyeballs grows exponentially, and then full monetization comes later. We believe that esports is one of the world’s fastest growing industries today, and the success of teams like Team Vitality show that there is real opportunity for growth in this market. We are well on the way to building one of the world’s first billion-dollar esports teams.”
-ends-
Footnotes and References
*BBC
Video of esports world champion, Rocket League player Kyle ‘Scrub Killa’ Robertson, and esports super-coach Mike ‘Gregan’ Ellis, are available to embed into stories relating to this release, using these links:
Gregan: https://youtu.be/uLN4S1LFVgI
Scrub Killa: https://youtu.be/LSg-rwTeBHk
Images are available to download here and must be attributed to: Team Vitality: https://drive.google.com/drive/folders/1Ol4_J_pdo8S7c6W-YZ8tkgTrfOFPd4Xd
About Rewired.GG
Rewired.GG is an esports venture fund investing in the talent and ideas that are driving the global growth of esports. In November Rewired.GG 2018 backed European esports leader Team Vitality with €20m of investment to create a global esports brand. The investment thesis of the Rewired.GG esports venture fund is that esports is at an exciting tipping point. The NFL earns around $50 per fan, but that number for esports is only $3.20*. Rewired.GG predicts that this upside potential revenue growth per fan combined with rapidly growing global audiences with rapidly-growing spending power, will generate significant future returns.
About Team Vitality
Team Vitality is an international esports organisation that was founded by Nicolas Maurer and Fabien Devide in 2013. The team has players from ten different nationalities and boasts some of the biggest players in the world, including the world No.1 Fifa player, world No.1 CS:GO player, and the world champion Rocket League squad. Team Vitality players compete in a portfolio of 9 games with 10 competitive teams. Team Vitality's main League of Legends roster competes in the League of Legends European Championship (LEC), which they joined after purchasing Gambit Gaming's spot. They are sponsored by Orange, Red Bull, Renault and Adidas.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191106005183/en/
Contact information
To request interviews please use the contact details below:
Helen Tarbet / Simon Compton / Kim van Beeck / Hannah Ratcliff (Buchanan Communications)
rewired@buchanan.uk.com
+44 207 466 5000
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
